Pluri Inc Stock Price, News & Analysis

Pluri Inc. (PLUR) reported significant growth and strategic developments in its fiscal year 2025. The company achieved nearly 400% revenue growth in the first nine months, reaching $938,000 compared to $230,000 in the same period last year, driven by CDMO and AgTech businesses. Pluri is expanding into the cultivated cacao and coffee markets to address supply chain challenges caused by climate change and rising demand. The company maintains a 69% stake in Ever After Foods, which secured a $10 million funding round led by strategic partners. While NIH and DoD funding for PLX-R18 development was discontinued, Pluri partnered with Hemafund for nuclear emergency response plans. The company is actively pursuing partnerships in the cocoa and coffee industries, focusing on commercial implementation and potential technology licensing opportunities.

Pluri Inc. (PLUR) has completed the acquisition of approximately 71% stake in Kokomodo , a cultivated cacao AgFoodTech company, for $4.5 million paid in 976,139 Common Shares. The strategic acquisition combines Pluri's mass-scale cell production expertise with Kokomodo's cellular agriculture technology for creating climate-resilient cacao.

Kokomodo will continue operating independently as a Pluri subsidiary, maintaining its mission, team, and brand identity under CEO Tal Govrin's leadership. The acquisition aims to accelerate Kokomodo's production capabilities and global expansion while addressing sustainability challenges in the cacao industry.

The global cacao market, valued at $13.5 billion in 2023, is projected to grow at a CAGR of 8.2% to reach $23.5 billion by 2030.

DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.

Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.

Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.

Pluri Inc. (PLUR) has strengthened its intellectual property portfolio with two new patents for 3D expansion of immune cells, granted by the USPTO and Israel. The patents specifically cover MAIT (Mucosal-Associated Invariant T) cell expansion technologies in large-scale bioreactors.

The company's placental MAIT cells platform aims to address solid tumor treatment, targeting the immune cell engineering market (projected at $11.7B by 2030) and cancer immunotherapy market ($136B in 2025). These cells offer unique advantages over conventional T cells, including lower alloreactivity and enhanced tumor-targeting capabilities.

Pluri's IP estate now encompasses over 250 patents pending, allowed, and granted. The technology enables commercial-scale production of 'off-the-shelf' immune cell therapies, with applications extending to Tumor Infiltrating Lymphocytes (TILs).

Pluri Inc. (PLUR) has signed an exclusive collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness. The three-year partnership focuses on stockpiling and distributing Pluri's PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS).

The collaboration aims to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals. If successful, the initiative could generate over $100 million in value for both parties. Hemafund will leverage its biobank infrastructure for storage and distribution across Ukraine.

This strategic initiative comes in response to recent security concerns, including a Russian drone strike on the Chernobyl nuclear power plant. The partnership encompasses:

• Secure storage and distribution systems
• Regulatory compliance support
• Clinical advancement opportunities
• Public and private funding initiatives

Ever After Foods (EAF) and Bühler announced a strategic collaboration to develop commercial-scale cultivated meat production systems. The partnership aims to bring to market a production system that enables commercial production at ten-fold lower scale than existing technologies.

The collaboration leverages EAF's proprietary edible packed-bed (EPB™) technology platform, which can reduce production costs by over 90% while achieving superior production efficiency. The system enables natural production of both muscle and fat tissues for beef, chicken, duck, and fish cells, ensuring exceptional replication of conventional meat.

EAF's technology offers enhanced nutritional value and superior flavor, working with select cultivated meat companies and industry leaders to accelerate global deployment. The partnership with Bühler aims to develop tailored solutions for sustainable scaling of cultivated meat production, moving beyond pharma-based technologies toward food-specific production methods.

Pluri Inc. (PLUR) has secured an additional $3.5 million investment from Merchant Adventure Fund, L.P., a major existing shareholder, bringing total recent financings to $10 million. The investment follows a recent $6.5 million private placement with global investor Alejandro Weinstein.

The new investment involves issuing 759,219 common shares at $4.61 per share and warrants to purchase 45,553 shares at $5.568 per share. The closing is expected around February 20, 2025. The recent $6.5 million investment from Weinstein includes an agreement to acquire Kokomodo and potentially enter the cacao market.

The funds will support Pluri's growth strategy as a global leader in cell-based technology, enabling expansion across pharma, foodtech, and agtech industries. The company views this additional investment as a strong vote of confidence in its vision, technology, and execution strategy.

Pluri Inc. (PLUR) has secured a $6.5 million strategic investment from global investor Alejandro Weinstein at $4.61 per share, representing a premium to market. The investment includes common shares, warrants, and pre-funded warrants. Concurrently, Pluri is acquiring a 71% stake in Kokomodo , an AgTech company specializing in cultivated cacao production, for $4.5 million in Pluri common shares.

The transactions aim to strengthen Pluri's position in sustainable food technologies. As part of the deal, Weinstein will join Pluri's Board of Directors. The investment closing is expected around January 31, 2025, while the Kokomodo acquisition is anticipated to complete in Q2 2025. Both transactions require shareholder approval and other regulatory clearances.

The global cacao market, valued at $13.5 billion in 2023, is projected to reach $23.5 billion by 2030 with an 8.2% CAGR.

Pluri Inc. (PLUR) congratulates Mesoblast on receiving FDA approval for the first MSC-based therapy treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). This milestone validates the therapeutic potential of Mesenchymal Stromal Cell (MSC) therapies in regenerative medicine. Pluri's CEO Yaky Yanay emphasized how this approval marks a significant advancement in cellular medicine and demonstrates the potential of regenerative therapies to transform healthcare by addressing root causes rather than just symptoms.

Pluri continues developing its proprietary 3D cell-expansion technology for MSC therapies, including PLacental eXpanded cells for treating conditions like Acute Radiation Syndrome and Knee Osteoarthritis.